U.S. Markets closed

Matinas BioPharma Holdings, Inc. (MTNB)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.8890-0.0520 (-5.53%)
At close: 4:00PM EDT

Matinas BioPharma Holdings, Inc.

1545 Route 206 South
Suite 302
Bedminster, NJ 07921
United States
908 443 1860
http://www.matinasbiopharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees21

Key Executives

NameTitlePayExercisedYear Born
Mr. Jerome D. Jabbour J.D.Co-Founder, CEO, Pres & Director644.79kN/A1974
Mr. Keith A. Kucinski CPA, M.B.A.Chief Financial Officer249.05kN/A1970
Dr. Theresa MatkovitsChief Devel. Officer380.62kN/A1967
Dr. James J. FergusonChief Medical Officer461.46kN/A1953
Dr. Raphael J. ManninoChief Scientific OfficerN/AN/A1947
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.

Corporate Governance

Matinas BioPharma Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.